{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:21Z","timestamp":1792896921178,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110048","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T02:50:36Z","timestamp":1701917436000},"page":"110048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials"],"prefix":"10.1016","volume":"190","author":[{"given":"Ilinca","family":"Popp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne D.W.","family":"Vaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Wieten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Bavafaye Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Degens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius F.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Rawluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110048_b0005","first-page":"04785","article-title":"Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"S0923\u20137534","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0010","doi-asserted-by":"crossref","first-page":"1901907","DOI":"10.1183\/13993003.01907-2019","article-title":"Immunotherapy for non-small cell lung cancer: a new therapeutic algorithm","volume":"55","author":"Berghmans","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.radonc.2023.110048_b0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110048_b0020","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110048_b0025","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0030","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0035","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110048_b0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110048_b0050","first-page":"JCO2201990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0055","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0060","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","article-title":"Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations","volume":"15","author":"Remon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0065","doi-asserted-by":"crossref","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","article-title":"Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2023.110048_b0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2023.110048_b0075","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-Lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0080","doi-asserted-by":"crossref","first-page":"S953","DOI":"10.1016\/j.annonc.2021.08.1799","article-title":"Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2\/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results","volume":"32","author":"Paz-Ares","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0085","doi-asserted-by":"crossref","first-page":"20200042","DOI":"10.1259\/bjr.20200042","article-title":"The abscopal effect 67 years later: From a side story to center stage","volume":"93","author":"Demaria","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.110048_b0090","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2016.07.013","article-title":"Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications","volume":"120","author":"Popp","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ijrobp.2020.11.053","article-title":"Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: a phase 1 study","volume":"109","author":"Van Limbergen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110048_b0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.radonc.2023.110048_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.radonc.2023.110048_b0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijrobp.2018.10.009","article-title":"An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models","volume":"103","author":"Markovsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110048_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2021-002973","article-title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1\/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","volume":"9","author":"Leighl","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0140","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/ijms20092173","article-title":"Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: A systematic review","volume":"20","author":"Chicas-Sett","year":"2019","journal-title":"Mol Sci"},{"key":"10.1016\/j.radonc.2023.110048_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13014-019-1222-3","article-title":"Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: A National Cancer Database analysis","volume":"14","author":"Foster","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0150","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/j.cllc.2021.02.005","article-title":"The NIPRO Study: an observational, retrospective, multicenter study on the safety of the radiotherapy and immunotherapy combination for advanced-stage NSCLC","volume":"22","author":"Perna","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0155","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.05.013","article-title":"Combination of SABR with anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma: results of a prospective multicenter observational study","volume":"114","author":"Chicas-Sett","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110048_b0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: The CHEERS phase 2 randomized clinical trial","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0170","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2023.110048_b0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","article-title":"Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response","volume":"101","author":"Zhang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110048_b0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","article-title":"Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer","volume":"108","author":"Yin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110048_b0185","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-023-00358-z","article-title":"Dose- and time-dependent systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer","volume":"7","author":"Gkika","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.621329","article-title":"Pre-treatment tumor growth rate predicts clinical outcomes of patients with advanced non-small cell lung cancer undergoing anti-PD-1\/PD-L1 therapy","volume":"10","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0195","doi-asserted-by":"crossref","unstructured":"Dall\u2019Olio FG, Parisi C, Marcolin L, Brocchi S, Caramella C, Conci N, et al. Monitoring tumor growth rate to predict immune checkpoint inhibitors\u2019 treatment outcome in advanced NSCLC. Ther Adv Med Oncol 14 2022 17588359211058391 10.1177\/17588359211058391.","DOI":"10.1177\/17588359211058391"},{"key":"10.1016\/j.radonc.2023.110048_b0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2013.07.023","article-title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors","volume":"82","author":"Griffioen","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0210","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/imt-2019-0131","article-title":"Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer","volume":"12","author":"Reinhorn","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.radonc.2023.110048_b0220","doi-asserted-by":"crossref","first-page":"xi28","DOI":"10.1093\/annonc\/mdz449.033","article-title":"79P-Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer","volume":"30","author":"Enomoto","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/s12885-021-08165-0","article-title":"Treatment beyond progression with anti-PD-1\/PD-L1 based regimens in advanced solid tumors: a systematic review","volume":"21","author":"Spagnolo","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.110048_b0230","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer","volume":"5","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110048_b0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncr.34565","article-title":"A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029","volume":"129","author":"Salous","year":"2023","journal-title":"Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T04:10:15Z","timestamp":1734235815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":47,"alternative-id":["S0167814023093556"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110048","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110048"}}